[PS4] Presidential Session 4
【E】

[PS4-4] Randomized phase III study of etoposide/cisplatin versus irinotecan/cisplatin in advanced digestive NEC: JCOG1213

^○Chigusa Morizane¹, Nozomu Machida², Yoshitaka Honma³, Takuji Okusaka¹, Narikazu Boku⁴, Ken Kato³, Shogo Nomura⁵, Nobuyoshi Hiraoka⁶, Shigeki Sekine⁶, Hirokazu Taniguchi⁶, Naohiro Okano⁷, Kensei Yamaguchi⁸, Takuji Sato⁹, Masafumi Ikeda¹⁰, Nobumasa Mizuno¹¹, Masato Ozaka¹², Tomoko Kataoka¹³, Masanori Terashima¹⁴, Yuko Kitagawa¹⁵, Junji Furuse⁷ (1.Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 2.Department of Gastroenterology, Kanagawa Cancer Center, 3.Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 4.Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5.JCOG Data Center/Operations Office, National Cancer Center Hospital, 6.Department of Diagnostic Pathology, National Cancer Center Hospital, 7.Department of Medical Oncology, Kyorin University Faculty of Medicine, 8.Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 9.Department of Gastroenterological Surgery, Kochi Health Sciences Center, 10.Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 11.Department of Gastroenterology, Aichi Cancer Center Hospital, 12.Hepato-Biliary-Pancreatic Medicine Department, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 13.Japan Clinical Oncology Group Operations Office, Clinical Research Support Office, National Cancer Center Hospital, 14.Division of Gastric Surgery, Shizuoka Cancer Center, 15.Department of Surgery, Keio University School of Medicine.)